Skip to main content
Equibles

Eric

Analyst

Goldman Sachs

Equibles does not estimate personal net worth.

About Eric

Eric is recorded as Analyst at Goldman Sachs. Eric has spoken on 2 earnings calls across 2 companies, most recently for Vir Biotechnology, Inc. on August 5, 2026. Those appearances were for Vir Biotechnology, Inc. (VIR) and UroGen Pharma Ltd. (URGN). The companies whose calls Eric spoke on are classified in the Healthcare sector.

Eric on recent calls

“A question about, you know, after the initial Eclipse 1 readout, what is the plan and timing for long-term extension data, and will the follow-up assess the durability of TND and whether patients could eventually discontinue treatment?”
Analyst — Goldman Sachs, Vir Biotechnology Second Quarter 2026 Corporate Update and Financial Results Conference Call ·
“I just wanted to elaborate a little bit more on the sequencing of adjuvant therapies here.”
Analyst — Goldman Sachs, UroGen Pharma Ltd. Q2 FY2026 Earnings Call ·

Affiliation history

  • Goldman Sachs

    Analyst

    Transcript header (unverified)

    Current

Company network

Recent activity